Weiss Ratings Reaffirms "Sell (D-)" Rating for Ventyx Biosciences (NASDAQ:VTYX)

Key Points

• Weiss Ratings has reaffirmed a “Sell (D-)” rating for Ventyx Biosciences, indicating concerns about the company's stock performance.
• Despite Weiss Ratings' position, Wall Street Zen upgraded the stock from a "sell" to a "hold" rating, reflecting mixed analyst opinions.
• Ventyx reported a quarterly earnings per share of ($0.38), which was better than the consensus estimate of ($0.45).

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities researchers at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

Separately, Wall Street Zen raised Ventyx Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $7.50.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX traded down $0.79 on Friday, hitting $5.81. The company had a trading volume of 12,438,341 shares, compared to its average volume of 8,437,870. Ventyx Biosciences has a 1-year low of $0.78 and a 1-year high of $7.82. The stock has a 50 day moving average price of $3.09 and a 200 day moving average price of $2.40.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.07. Equities analysts expect that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Ventyx Biosciences during the first quarter valued at approximately $28,000. Hudson Bay Capital Management LP acquired a new position in Ventyx Biosciences during the second quarter valued at approximately $34,000. Pallas Capital Advisors LLC acquired a new position in Ventyx Biosciences during the second quarter valued at approximately $38,000. Engineers Gate Manager LP acquired a new position in Ventyx Biosciences during the second quarter valued at approximately $42,000. Finally, Jump Financial LLC acquired a new position in Ventyx Biosciences during the second quarter valued at approximately $53,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.